Mostrando las entradas con la etiqueta The Lancet. Mostrar todas las entradas
Mostrando las entradas con la etiqueta The Lancet. Mostrar todas las entradas

04 diciembre, 2013

Statins: new American guidelines for prevention of cardiovascular disease

Just change the values or target population and more people will receive more medication, is it a real  major step in the prevention of cardiovascular disease ?  Not for me, what do you think after read the new guidelines ? Are real evidences for the use statins also in primary prevention ? One billons of persons are treated today, all over the world, with this kind of drugs, and the first blockbuster drugs is Atorvastatin.........what about the evidences, and the hundreds of articles against that ? Think for yourself......

Paul M Ridker aEmail Address, Nancy R Cook a

Guidelines released on Nov 13, 2013, by the American Heart Association (AHA) and the American College of Cardiology (ACC) for the management of cholesterol are a major step in the right direction. 1 These new guidelines emphasise prevention of stroke as well as heart disease, focus appropriately on statin therapy rather than alternative unproven therapeutic agents, and recognise that more intensive treatment is superior to less intensive treatment for many patients........full text.
Statins: new American guidelines for prevention of cardiovascular disease
Paul M Ridker,Nancy R Cook
The Lancet - 30 November 2013 ( Vol. 382, Issue 9907, Pages 1762-1765 )
DOI: 10.1016/S0140-6736(13)62388-0

16 septiembre, 2011

Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies

Mirena IntraUterine SystemImage via Wikipedia
The Lancet Oncology, Early Online Publication, 13 September 2011
doi:10.1016/S1470-2045(11)70223-6Cite or Link Using DOI

Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies

Summary

Background

Intrauterine device (IUD) use has been shown to reduce the risk of endometrial cancer, but little is known about its association with cervical cancer risk. We assessed whether IUD use affects cervical human papillomavirus (HPV) infection and the risk of developing cervical cancer.

Methods

We did a pooled analysis of individual data from two large studies by the International Agency for Research on Cancer and Institut Català d'Oncologia research programme on HPV and cervical cancer; one study included data from ten case—control studies of cervical cancer done in eight countries, and the other included data from 16 HPV prevalence surveys of women from the general population in 14 countries. 2205 women with cervical cancer and 2214 matched control women without cervical cancer were included from the case—control studies, and 15 272 healthy women from the HPV surveys. Information on IUD use was obtained by personal interview. HPV DNA was tested by PCR-based assays. Odds ratios and 95% CIs were estimated using multivariate unconditional logistic regression for the associations between IUD use, cervical HPV DNA, and cervical cancer.

Findings

After adjusting for relevant covariates, including cervical HPV DNA and number of previous Papanicolaou smears, a strong inverse association was found between ever use of IUDs and cervical cancer (odds ratio 0·55, 95% CI 0·42—0·70; p<0·0001). A protective association was noted for squamous-cell carcinoma (0·56, 0·43—0·72; p<0·0001), adenocarcinoma and adenosquamous carcinoma (0·46, 0·22—0·97; p=0·035), but not among HPV-positive women (0·68, 0·44—1·06; p=0·11). No association was found between IUD use and detection of cervical HPV DNA among women without cervical cancer.

Interpretation

Our data suggest that IUD use might act as a protective cofactor in cervical carcinogenesis. Cellular immunity triggered by the device might be one of several mechanisms that could explain our findings.

Funding

Instituto de Salud Carlos III; Agència de Gestió d'Ajuts Universitaris i Recerca; Marató TV3 Foundation; Bill & Melinda Gates Foundation; International Agency for Research on Cancer; European Community; Fondo de Investigaciones Sanitarias, Spain; Preventiefonds, Netherlands; Programa Interministerial de Investigación y Desarrollo, Spain; Conselho Nacional de Desenvolvimiento Cientifico e Tecnologico, Brazil; and Department of Reproductive Health & Research, WHO.

Enhanced by Zemanta

09 septiembre, 2011

Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial



Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial
Ms Heather Powell MMedSc,Vanessa E Murphy PhD,Prof D Robin Taylor MD,Prof Michael J Hensley PhD,Kirsten McCaffery PhD,Warwick Giles PhD,Vicki L Clifton PhD,Prof Peter G Gibson MBBS
The Lancet - 10 September 2011 ( Vol. 378, Issue 9795, Pages 983-990 )
DOI: 10.1016/S0140-6736(11)60971-9

Background


ber 201

Asthma exacerbations during pregnancy are common and can be associated with substantial maternal and fetal morbidity. Treatment decisions based on sputum eosinophil counts reduce exacerbations in non-pregnant women with asthma, but results with the fraction of exhaled nitric oxide (FENO) to guide management are equivocal. We tested the hypothesis that a management algorithm for asthma in pregnancy based on FENO and symptoms would reduce asthma exacerbations.

Methods

We undertook a double-blind, parallel-group, controlled trial in two antenatal clinics in Australia. 220 pregnant, non-smoking women with asthma were randomly assigned, by a computer-generated random number list, before 22 weeks’ gestation to treatment adjustment at monthly visits by an algorithm using clinical symptoms (control group) or FENO concentrations (active intervention group) used to uptitrate (FENO >29 ppb) or downtitrate (FENO <16 ppb) inhaled corticosteroid dose. Participants, caregivers, and outcome assessors were masked to group assignment. Longacting β2 agonist and minimum dose inhaled corticosteroid were used to treat symptoms when FENO was not increased. The primary outcome was total asthma exacerbations (moderate and severe). Analysis was by intention to treat. This study is registered with the Australian and New Zealand Clinical Trials Registry, number 12607000561482.

Findings

111 women were randomly assigned to the FENO group (100 completed) and 109 to the control group (103 completed). The exacerbation rate was lower in the FENO group than in the control group (0·288 vs 0·615 exacerbations per pregnancy; incidence rate ratio 0·496, 95% CI 0·325—0·755; p=0·001). The number needed to treat was 6. In the FENO group, quality of life was improved (score on short form 12 mental summary was 56·9 [95% CI 50·2—59·3] in FENO group vs 54·2 [46·1—57·6] in control group; p=0·037) and neonatal hospitalisations were reduced (eight [8%] vs 18 [17%]; p=0·046).

Interpretation

Asthma exacerbations during pregnancy can be significantly reduced with a validated FENO-based treatment algorithm.

Funding

National Health and Medical Research Council of Australia.

29 julio, 2011

Vaccine production, distribution, access, and uptake

The LancetImage via Wikipedia
The Lancet, Volume 378, Issue 9789, Pages 428 - 438, 30 July 2011
Published Online: 09 June 2011

doi:10.1016/S0140-6736(11)60478-9Cite or Link Using DO

Vaccine production, distribution, access, and uptake

Jon Smith PhD a, Prof Marc Lipsitch DPhil b, Prof Jeffrey W Almond PhD a Corresponding AuthorEmail Address

Summary

For human vaccines to be available on a global scale, complex production methods, meticulous quality control, and reliable distribution channels are needed to ensure that the products are potent and effective at the point of use. The technologies used to manufacture different types of vaccines can strongly affect vaccine cost, ease of industrial scale-up, stability, and, ultimately, worldwide availability. The complexity of manufacturing is compounded by the need for different formulations in different countries and age-groups. Reliable vaccine production in appropriate quantities and at affordable prices is the cornerstone of developing global vaccination policies. However, to ensure optimum access and uptake, strong partnerships are needed between private manufacturers, regulatory authorities, and national and international public health services. For vaccines whose supply is insufficient to meet demand, prioritisation of target groups can increase the effect of these vaccines. In this report, we draw from our experience of vaccine development and focus on influenza vaccines as an example to consider production, distribution, access, and other factors that affect vaccine uptake and population-level effectiveness.


23 julio, 2011

Debt crisis strains Greece's ailing health system

Health care systems                            Image via Wikipedia
The Lancet, Volume 378, Issue 9788, Pages 303 - 304, 23 July 2011

Eva Karamanoli
The financial turmoil in Greece is putting pressure on the country's creaking health system as more people turn to public rather than private hospitals for care. Eva Karamanoli reports from Athens.
It is a few minutes after midnight. In the emergency room of a major national hospital in Athens, the corridors look like a conflict zone. People suffering in pain lie on camp beds while waiting in the endless queue of patients who need major or minor medical help. “The doctors and the nurses are very kind and helpful but I think I will be waiting here till morning”, says a 46-year-old ago with chest pain.
She is right. Half the patients will wait until dawn to be examined by a doctor. Those who will need to be hospitalised will probably lie in camp beds in the hospital's corridor until noon, and only one or two of them who need urgent medical care will be placed in a bed in one of the hospital's units—not necessarily the appropriate one as it might already be overcrowded.
The doors open and paramedics bring in a 25-year-old man who has just been involved in a car accident. There is blood everywhere. Two doctors rush to his aid. “Give me a pair of gloves”, orders one to the other. “Give me 5 minutes. I'll have to go to the surgery department to get some. We're out of stock”, is the reply.
The situation described above is typical of emergency rooms in Greek hospitals over the past few years. The financial crisis has made things considerably worse. The reasons are simple. Every day, more and more people choose to be treated in national hospitals rather than private ones, so the faults of an old and declining national health system are more easily exposed.
Additionally, most of the 1.5 million immigrants that reside in Greece and visit the national hospitals to be treated have no social or medical insurance but they do get medical help. “We took the oath of Hippocrates”, I hear a doctor say, and I think that is probably one of the key things that keeps the national health system going: the loving honour. But for how long is anybody's guess.
“The financial crisis has influenced the morale of doctors, nurses, and all other medical staff. In my opinion, this is the most serious consequence. In addition, the general financial predicament the country is facing has a negative impact in hospital finances”, says Grigoris Paspatis, head of the gastroenterology department at Venizeleion Hospital on the island of Crete and president of the Heraklion Medical Association. “Every day, we face practical problems such as lack of stitches, gauzes, IVs as well as basic and standard essential medical supplies, including broken equipment that can't be fixed or kept operational, as the hospital owes money to its suppliers.”
The problem seems to be greater in the hospitals of Athens because of the city's overpopulation and crowding. In many cases hospitals trade essentials between them, and due to equipment being out-of-order, doctors often advise patients to visit other hospitals to have their medical tests done.
According to the latest findings of the National Statistic Force, Greece spends €25 billion each year on medical services, coming sixth worldwide in terms of spending on health. National hospitals owe about €6.5 billion to various medical suppliers for their products and services, of which €1.2 billion is owed to drug companies. As far as the national health insurance services are concerned, they owe €4.5 billion, of which about 1 billion is owed to pharmacists. “A pharmaceutical supplier must wait for at least 6 months in order to get paid from a national health insurance for medicine prescribed“, says Theodore Abatzoglou, president of the Hellenic Pharmaceutical Association.
In a time when Greece needs to cut down spending on every public sector, including the health sector, spending continues to rise. It is estimated that 7% of the national expenditure on health is on drugs alone. This estimate does not take into account the fact that drug companies sell their products directly to hospitals to maximise their profits.
“In order to cut down on medical costs, the government needs to re-examine the operational costs of hospitals. One way is to put in full operation the in-hospital electronic drug prescription system in order to reduce expenses”, says Abatzoglou.
Click to toggle image size
Full-size image (66K) AFP/Getty Images
Greek doctors protest in the centre of Athens against proposed cuts to health care
Click to toggle image size
Full-size image (53K) Reuters
Overcrowding in Greece's hospitals has meant long waiting times for many patients
The ministries of finance and health owe money to the hospitals, national health insurance services owe money to the pharmacists and the hospitals, and they, in turn, owe money to the suppliers and, thus, an endless cycle is perpetuated—a cycle that has to be broken for the health system to operate effectively and efficiently once again.
According to official data from the Ministry of Health, the total expenses for health (hospitals, national health insurance services, etc) exceeded €7 billion, of which €3 billion was the cost for national hospital supplies, in 2009. In 2010, the cost of hospital supplies was reduced to €2.6 billion. With a series of austerity measures the Ministry of Health intends to earn a further €350 million in cut backs in 2011.
Over the next few months, the Ministry of Health plans to implement a reduction in drug prescriptions. A list of medicines that are approved and covered by the national health system will be given to hospitals and drug suppliers. If a drug which is not included in the list needs to be prescribed, the patient will have to pay for it themselves. This move is being made to cut down on the expensive drugs that doctors tend to prescribe while there are cheaper and equally effective alternatives.
George Papatheodoridis, associate professor of medicine at Athens University who also practises at Hippokration Hospital, Athens, explains that “this is one of the many efforts that is being done in order to cut down on costs, but sometimes the solutions are not in the patients' best interest”. Lots of drugs, not vital but widely used, such as acne creams, cough syrups, and medicine for vascular diseases will be excluded and so will all drugs that exceed the average cost of their category. “This is not safe because most of these drugs are widely used all over Europe effectively. Besides, one must have in mind that each drug has its own side-effects, dosage, time of treatment, etc”, says Papatheodoridis.
In Evangelismos Hospital, the biggest hospital in Greece, located in the centre of Athens, drugs are already electronically prescribed. “Soon Evangelismos will be the first e-hospital in Greece. Everything will be recorded digitally and will thus be easily verified”, says Michael Theodorou, the hospital's manager.
According to Theodorou, the greatest part of the institution's expenses is allocated to medical supplies and equipment maintenance and repairs. “We manage to cover our expenses and pay our suppliers within 90 days maximum, so the lack of supplies is due to delayed orders.” As Theodorou points out “the financial crisis may be a chance for the national health system—and Greece in general—to reboot and operate effectively again. As far as Evangelismos Hospital is concerned, the key is for the staff working there to adapt to a culture of sensible consumption. “If something is needed and asked for, it will be delivered, but we have to stop the uncontrolled and unreasonable waste of money.”
Meanwhile, the Ministry of Health has proposed a plan to reduce the number of clinics and hospital managers in the national health system to make it more flexible and effective.
We need to develop the national health system in a way that serves the Greeks, says Greece's Minister of Health George Loverdos. According to the minister's plan, the 1900 clinics that operate in the country will be reduced to 1600 and will be run by 83 managers (at present, there are 131). The minister is due to present the plan at the end of this month and it will then be discussed between the parties involved.
The plan to merge hospitals though, is highly questioned by many respectable doctors and academics, for example Emmanuel Kalokairinos, president of the Hellenic Doctors Association, who points out that “There's a lot to be discussed. At winter some islands are cut off and often the transportation of a patient, even to the nearest island which has a medical unit, is very difficult while in Athens, if hospitals are merged, the situation will become very difficult when they are on call. The situation will get even worse as the major hospitals reach their full capacity.”
To avoid this problem, the Ministry of Health, beginning in September, will operate a new body for “simple, everyday health problems”, such as coughs, blood pressure disorders, and minor accidents, that until now were dealt with by hospitals. “For the first time all Greeks will have an equal treatment from a body that will be unified with the national health system. Hospitals will be unblocked”, said Health Minister Loverdos.
“In order for the new body to operate, the cost is estimated at €8 million yearly. Also, the working status of the doctors is still unknown”, Kalokairinos concludes.
There is a lot still to be discussed. But in the midst of the financial crisis in Greece, plans are being implemented and actions are being taken to improve the health system. Perhaps, the debt crisis is a chance for health care in Greece to progress after all..

Enhanced by Zemanta

13 julio, 2011

Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial

Age-standardised disability-adjusted life year...                          Image via WikipediaGriffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011 Jun 24. (Original) PMID: 21705063


BACKGROUND: Intensive treatment of multiple cardiovascular risk factors can halve mortality among people with established type 2 diabetes. We investigated the effect of early multifactorial treatment after diagnosis by screening.
METHODS: In a pragmatic, cluster-randomised, parallel-group trial done in Denmark, the Netherlands, and the UK, 343 general practices were randomly assigned screening of registered patients aged 40-69 years without known diabetes followed by routine care of diabetes or screening followed by intensive treatment of multiple risk factors. The primary endpoint was first cardiovascular event, including cardiovascular mortality and morbidity, revascularisation, and non-traumatic amputation within 5 years. Patients and staff assessing outcomes were unaware of the practice`s study group assignment. Analysis was done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00237549.
FINDINGS: Primary endpoint data were available for 3055 (99.9%) of 3057 screen-detected patients. The mean age was 60.3 (SD 6.9) years and the mean duration of follow-up was 5.3 (SD 1.6) years. Improvements in cardiovascular risk factors (HbA(1c) and cholesterol concentrations and blood pressure) were slightly but significantly better in the intensive treatment group. The incidence of first cardiovascular event was 7.2% (13.5 per 1000 person-years) in the intensive treatment group and 8.5% (15.9 per 1000 person-years) in the routine care group (hazard ratio 0.83, 95% CI 0.65-1.05), and of all-cause mortality 6.2% (11.6 per 1000 person-years) and 6.7% (12.5 per 1000 person-years; 0.91, 0.69-1.21), respectively.
INTERPRETATION: An intervention to promote early intensive management of patients with type 2 diabetes was associated with a small, non-significant reduction in the incidence of cardiovascular events and death.
FUNDING: National Health Service Denmark, Danish Council for Strategic Research, Danish Research Foundation for General Practice, Danish Centre for Evaluation and Health Technology Assessment, Danish National Board of Health, Danish Medical Research Council, Aarhus University Research Foundation, Wellcome Trust, UK Medical Research Council, UK NIHR Health Technology Assessment Programme, UK National Health Service R&D, UK National Institute for Health Research, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, Novo Nordisk, Astra, Pfizer, GlaxoSmithKline, Servier, HemoCue, Merck.

01 octubre, 2008

Telmisartan: estudio Trascend

Publicado en Lancet: Estudio Trascend

- 5926 pacientes, 2954 recibieron 80 mgr de Telmisartan, 2972 placebo. Estudio aleatorizado, controlado.

- Analisis por intencion de tratar. Seguimiento entre 51 a 64 meses.

- Disminucion de la TA media: HR 0,92 (IC 95% 0.81-1.05). No significativo.

- Resultados de muerte cardiovascular, IAM, ACV: 0,87 (IC 95% 0.76-1.00). Significativo a p 0,05 pero no a 0,01.

- Hospitalizacion por eventos cardiovasculares: RR 0,92 (CI 95% 0.85-0.99). No significativo a p 0.01.

- Telmisartan fue bien tolerado en pacientes que no toleran IECAs. Aunque el medicamento no mostro diferencias significativas en los resultados primariso, los cuales incluyeron fallta cardica, y una modesta reduccion del riesgo de padecer una serie de eventos cardiovascularses mayores compuestos (muerte cardiovascular, IAM, ACV).

- Financiamiento: Boheringer Ingelheim.

Conclusion: para que sirve el telmisartan????


Telmisartan: estudio Trascend

Publicado en Lancet: Estudio Trascend

- 5926 pacientes, 2954 recibieron 80 mgr de Telmisartan, 2972 placebo. Estudio aleatorizado, controlado.

- Analisis por intencion de tratar. Seguimiento entre 51 a 64 meses.

- Disminucion de la TA media: HR 0,92 (IC 95% 0.81-1.05). No significativo.

- Resultados de muerte cardiovascular, IAM, ACV: 0,87 (IC 95% 0.76-1.00). Significativo a p 0,05 pero no a 0,01.

- Hospitalizacion por eventos cardiovasculares: RR 0,92 (CI 95% 0.85-0.99). No significativo a p 0.01.

- Telmisartan fue bien tolerado en pacientes que no toleran IECAs. Aunque el medicamento no mostro diferencias significativas en los resultados primariso, los cuales incluyeron fallta cardica, y una modesta reduccion del riesgo de padecer una serie de eventos cardiovascularses mayores compuestos (muerte cardiovascular, IAM, ACV).

- Financiamiento: Boheringer Ingelheim.

Conclusion: para que sirve el telmisartan????


Telmisartan: estudio Trascend

Publicado en Lancet: Estudio Trascend

- 5926 pacientes, 2954 recibieron 80 mgr de Telmisartan, 2972 placebo. Estudio aleatorizado, controlado.

- Analisis por intencion de tratar. Seguimiento entre 51 a 64 meses.

- Disminucion de la TA media: HR 0,92 (IC 95% 0.81-1.05). No significativo.

- Resultados de muerte cardiovascular, IAM, ACV: 0,87 (IC 95% 0.76-1.00). Significativo a p 0,05 pero no a 0,01.

- Hospitalizacion por eventos cardiovasculares: RR 0,92 (CI 95% 0.85-0.99). No significativo a p 0.01.

- Telmisartan fue bien tolerado en pacientes que no toleran IECAs. Aunque el medicamento no mostro diferencias significativas en los resultados primariso, los cuales incluyeron fallta cardica, y una modesta reduccion del riesgo de padecer una serie de eventos cardiovascularses mayores compuestos (muerte cardiovascular, IAM, ACV).

- Financiamiento: Boheringer Ingelheim.

Conclusion: para que sirve el telmisartan????


23 septiembre, 2008

Fiebre, paracetamol y riesgo de asma, rinoconjuntivitis y eczema

Summary

Background

Exposure to paracetamol during intrauterine life, childhood, and adult life may increase the risk of developing asthma. We studied 6–7-year-old children from Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC) programme to investigate the association between paracetamol consumption and asthma.

Methods

As part of Phase Three of ISAAC, parents or guardians of children aged 6–7 years completed written questionnaires about symptoms of asthma, rhinoconjunctivitis, and eczema, and several risk factors, including the use of paracetamol for fever in the child's first year of life and the frequency of paracetamol use in the past 12 months. The primary outcome variable was the odds ratio (OR) of asthma symptoms in these children associated with the use of paracetamol for fever in the first year of life, as calculated by logistic regression.

Findings

205 487 children aged 6–7 years from 73 centres in 31 countries were included in the analysis. In the multivariate analyses, use of paracetamol for fever in the first year of life was associated with an increased risk of asthma symptoms when aged 6–7 years (OR 1·46 [95% CI 1·36–1·56]). Current use of paracetamol was associated with a dose-dependent increased risk of asthma symptoms (1·61 [1·46–1·77] and 3·23 [2·91–3·60] for medium and high use vs no use, respectively). Use of paracetamol was similarly associated with the risk of severe asthma symptoms, with population-attributable risks between 22% and 38%. Paracetamol use, both in the first year of life and in children aged 6–7 years, was also associated with an increased risk of symptoms of rhinoconjunctivitis and eczema.

Interpretation

Use of paracetamol in the first year of life and in later childhood, is associated with risk of asthma, rhinoconjunctivitis, and eczema at age 6 to 7 years. We suggest that exposure to paracetamol might be a risk factor for the development of asthma in childhood.

Funding

The BUPA Foundation, the Health Research Council of New Zealand, the Asthma and Respiratory Foundation of New Zealand, the Hawke's Bay Medical Research Foundation, the Waikato Medical Research Foundation, Glaxo Wellcome New Zealand, the New Zealand Lottery Board, Astra Zeneca New Zealand, and Glaxo Wellcome International Medical Affairs.

Affiliations

a. Medical Research Institute of New Zealand, Wellington, New Zealand
b. Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
c. Department of Medicine, Otago University Wellington, Wellington, New Zealand
d. Dr von Haunersches University Children's Hospital, Ludwig-Maximilians University Munich, Germany
e. Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong, SAR China
f. Department of Medicine, University of Malta, Malta
g. School of Population Health, University of Auckland, Auckland, New Zealand

Corresponding Author InformationCorrespondence to: Prof Richard Beasley, Medical Research Institute of New Zealand, PO Box 10055, Wellington 6143, New Zealand

Fiebre, paracetamol y riesgo de asma, rinoconjuntivitis y eczema

Summary

Background

Exposure to paracetamol during intrauterine life, childhood, and adult life may increase the risk of developing asthma. We studied 6–7-year-old children from Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC) programme to investigate the association between paracetamol consumption and asthma.

Methods

As part of Phase Three of ISAAC, parents or guardians of children aged 6–7 years completed written questionnaires about symptoms of asthma, rhinoconjunctivitis, and eczema, and several risk factors, including the use of paracetamol for fever in the child's first year of life and the frequency of paracetamol use in the past 12 months. The primary outcome variable was the odds ratio (OR) of asthma symptoms in these children associated with the use of paracetamol for fever in the first year of life, as calculated by logistic regression.

Findings

205 487 children aged 6–7 years from 73 centres in 31 countries were included in the analysis. In the multivariate analyses, use of paracetamol for fever in the first year of life was associated with an increased risk of asthma symptoms when aged 6–7 years (OR 1·46 [95% CI 1·36–1·56]). Current use of paracetamol was associated with a dose-dependent increased risk of asthma symptoms (1·61 [1·46–1·77] and 3·23 [2·91–3·60] for medium and high use vs no use, respectively). Use of paracetamol was similarly associated with the risk of severe asthma symptoms, with population-attributable risks between 22% and 38%. Paracetamol use, both in the first year of life and in children aged 6–7 years, was also associated with an increased risk of symptoms of rhinoconjunctivitis and eczema.

Interpretation

Use of paracetamol in the first year of life and in later childhood, is associated with risk of asthma, rhinoconjunctivitis, and eczema at age 6 to 7 years. We suggest that exposure to paracetamol might be a risk factor for the development of asthma in childhood.

Funding

The BUPA Foundation, the Health Research Council of New Zealand, the Asthma and Respiratory Foundation of New Zealand, the Hawke's Bay Medical Research Foundation, the Waikato Medical Research Foundation, Glaxo Wellcome New Zealand, the New Zealand Lottery Board, Astra Zeneca New Zealand, and Glaxo Wellcome International Medical Affairs.

Affiliations

a. Medical Research Institute of New Zealand, Wellington, New Zealand
b. Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
c. Department of Medicine, Otago University Wellington, Wellington, New Zealand
d. Dr von Haunersches University Children's Hospital, Ludwig-Maximilians University Munich, Germany
e. Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong, SAR China
f. Department of Medicine, University of Malta, Malta
g. School of Population Health, University of Auckland, Auckland, New Zealand

Corresponding Author InformationCorrespondence to: Prof Richard Beasley, Medical Research Institute of New Zealand, PO Box 10055, Wellington 6143, New Zealand